Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
33actual
Sites
13
Countries
Canada, China, Singapore +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-20 | actual | When the study began enrolling |
| Primary completion | 2025-12-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-22 | actual | The whole study's end, after follow-up |
| First posted | 2022-07-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neoplasm
Interventions
- Biological: SAR444200
- Biological: Atezolizumab — also filed as Tecentriq®
Primary outcomes
what the primary-completion date above is the date OFPart 1A and 1B: Number of participants with Dose Limiting Toxicities (DLTs)
measured For Part 1A: from the Cycle 1, Day 1 up to Day 21For Part 1B: from Cycle 2 Day 1 up to Day 21
Part 1A and 1B: Number of participants with Adverse Events (AEs)
measured the time from the first dose of study interventions up to 30 days after last dose of study interventions
Part 2A: Objective Response Rate (ORR)
measured From baseline to the end of expansion study (up to 2 years)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed